Holen Sie sich die Stockscreener-App
15.81
0.75%
-0.085
Schlusskurs vom Vortag:
$15.90
Offen:
$15.8
24-Stunden-Volumen:
129.51K
Relative Volume:
0.13
Marktkapitalisierung:
$2.03B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-7.3374
EPS:
-2.1554
Netto-Cashflow:
-
1W Leistung:
-3.07%
1M Leistung:
+9.97%
6M Leistung:
+29.66%
1J Leistung:
+0.00%
1-Tages-Spanne:
$15.72
$16.23
1-Wochen-Bereich:
$15.40
$16.62
52-Wochen-Spanne:
$11.00
$22.67
Generate Biomedicines Inc Stock (GENB) Company Profile
Firmenname
Generate Biomedicines Inc
Sektor
Branche
Telefon
888-469-0055
Adresse
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
15.80 | 2.04B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
522.04 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.73 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.27 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-24 | Eingeleitet | Goldman | Buy |
| 2026-03-24 | Eingeleitet | Guggenheim | Buy |
| 2026-03-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-03-24 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Generate Biomedicines Inc Aktie (GENB) Neueste Nachrichten
H.C. Wainwright reiterates Buy on Generate Biomedicines stock By Investing.com - Investing.com Canada
Generate Biomedicines to Present at Upcoming Investor Conferences - Quiver Quantitative
Five September talks will stream online from Generate Biomedicines - Stock Titan
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Layoff Tracker: TScan axes 75% of workforce, prioritizes solid tumor program - BioSpace
Director at Generate Biomedicines (GENB) sells 1,000 shares near $16 - Stock Titan
Frances Arnold plans 2026 stock sale in Generate Biomedicines (NASDAQ: GENB) - Stock Titan
Director at Generate Biomedicines (GENB) lines up a major stock sale - Stock Titan
Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data - Investing.com UK
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Companies Like Generate Biomedicines (NASDAQ:GENB) Are In A Position To Invest In Growth - simplywall.st
Nvidia GPUs Are Table Stakes in AI Drug Discovery, Generate Biomedicines CTO Says - finance.biggo.com
Generate Biomedicines Reports Premature Release of GB-0895 Clinical Posters Ahead of ERS Congress 2026 - Kalkine Media
Certain Warrants of Generate Biomedicines, Inc. are subject to a Lock-Up Agreement Ending on 26-AUG-2026. - marketscreener.com
Generate Biomedicines shares jump 20% ahead of post-IPO lock-up expiry - Pluang
Nvidia backs Generate Biomedicines in AI drug discovery push - scanx.trade
Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Generate Biomedicines Inc's (NASDAQ:GENB) Lock-Up Period To End on August 26th - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Shares Up 4.9%Still a Buy? - MarketBeat
8 Stocks Nvidia Has Invested In - US News Money
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Shares Fall Following Q2 Financial Results - marketscreener.com
Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M - marketscreener.com
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business ... - Caledonian Record
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Generate Biomedicines: Q2 Earnings Snapshot - marketscreener.com
Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash - TradingView
Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary - TradingView
GENB: Phase 3 clinical and AI-driven pipeline progress offset by rising R&D costs and net loss - TradingView
Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO - Stock Titan
Generate Biomedicines, Inc. (GENB) Return On Assets (TTM) - Zacks Investment Research
Generate Biomedicines (GENB) Rallies 4.36% as Biotech Sentiment ShiftsMomentum Stock Picks - vinanet.vn
Generate Biomedicines, Inc. Revenue Breakdown – NASDAQ:GENB - TradingView
JPMorgan Small Cap Value Portfolio's Generate Biomedicines Inc(GENB) Holding History - GuruFocus
Generate Biomedicines, Inc. (GENB) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted (NASDAQ:GENB) - Seeking Alpha
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
Price to cash flow ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Surges 5.96% – Support and Resistance Levels in FocusVolatility Stop - dars.gov.et
Price to sales forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Consolidates Near Upper Bound as Bulls Test ResistanceRegression Channel - dars.gov.et
Price to earnings forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Number of shareholders of Generate Biomedicines, Inc. – BX:GENB - TradingView
Finanzdaten der Generate Biomedicines Inc-Aktie (GENB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):